AU2016321659A1 - Formulation having controlled, delayed active-ingredient release - Google Patents

Formulation having controlled, delayed active-ingredient release Download PDF

Info

Publication number
AU2016321659A1
AU2016321659A1 AU2016321659A AU2016321659A AU2016321659A1 AU 2016321659 A1 AU2016321659 A1 AU 2016321659A1 AU 2016321659 A AU2016321659 A AU 2016321659A AU 2016321659 A AU2016321659 A AU 2016321659A AU 2016321659 A1 AU2016321659 A1 AU 2016321659A1
Authority
AU
Australia
Prior art keywords
release
active ingredient
tablet
tablets
propranolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016321659A
Other languages
English (en)
Inventor
Finn BAUER
Gudrun BIRK
Dieter Lubda
Guenter Moddelmog
Roberto Ognibene
Thorsten Wedel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2016321659A1 publication Critical patent/AU2016321659A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016321659A 2015-09-14 2016-08-25 Formulation having controlled, delayed active-ingredient release Abandoned AU2016321659A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15185028.6 2015-09-14
EP15185028 2015-09-14
EP15189045.6 2015-10-09
EP15189045 2015-10-09
PCT/EP2016/001430 WO2017045742A1 (de) 2015-09-14 2016-08-25 Formulierung mit kontrollierter, verzögerter wirkstoffreisetzung

Publications (1)

Publication Number Publication Date
AU2016321659A1 true AU2016321659A1 (en) 2018-05-10

Family

ID=56855404

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016321659A Abandoned AU2016321659A1 (en) 2015-09-14 2016-08-25 Formulation having controlled, delayed active-ingredient release

Country Status (8)

Country Link
US (2) US10874615B2 (https=)
EP (1) EP3349733A1 (https=)
JP (1) JP6841819B2 (https=)
KR (1) KR20180052126A (https=)
CN (1) CN108024966A (https=)
AU (1) AU2016321659A1 (https=)
CA (1) CA2998422A1 (https=)
WO (1) WO2017045742A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160235709A1 (en) 2012-08-31 2016-08-18 Molecular product management LLC Limited release lingual thioctic acid delivery systems
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58502097A (ja) * 1981-12-18 1983-12-08 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド ポリビニルアルコ−ルおよびポリエチレングリコ−ルの拡張性格子
JPH02502720A (ja) * 1987-03-25 1990-08-30 イー・アイ・デユポン・デ・ニモアス・アンド・カンパニー 活性物質を錠剤にするためのビニルアルコールホモ重合体および共重合体の使用
US6495656B1 (en) * 1990-11-30 2002-12-17 Eastman Chemical Company Copolyesters and fibrous materials formed therefrom
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US5838571A (en) * 1996-01-29 1998-11-17 Alza Corporation Tablet press monitoring and controlling method and apparatus
WO2002003965A1 (en) * 2000-07-06 2002-01-17 Delsys Pharmaceutical Corporation Method for formulating healthcare products with enhanced stability
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
WO2004050066A1 (en) * 2002-11-27 2004-06-17 The University Of Georgia Research Foundation, Inc. Microspheres and related processes and pharmaceutical compositions
US7241838B2 (en) * 2003-12-19 2007-07-10 Eastman Chemical Company Blends of aliphatic-aromatic copolyesters with ethylene-vinyl acetate copolymers
US7368503B2 (en) * 2003-12-22 2008-05-06 Eastman Chemical Company Compatibilized blends of biodegradable polymers with improved rheology
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US9238073B2 (en) * 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
MY164765A (en) * 2007-10-10 2018-01-30 Avantor Performance Mat Llc Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
ES2401912T3 (es) * 2008-09-17 2013-04-25 Siegfried Ltd. Granulado que contiene nicotina
CN102695501A (zh) * 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 碎裂水凝胶
JP2013241341A (ja) * 2012-05-17 2013-12-05 Nisshin Kasei Kk マトリックス製剤用基剤、及び該基剤を用いた徐放性製剤
GB201412413D0 (en) * 2014-07-11 2014-08-27 Revolymer Uk Ltd Encapsulated benefit agent particles
WO2016015814A1 (de) * 2014-07-30 2016-02-04 Merck Patent Gmbh Pulverförmige, direkt verpressbare polyvinlalkohol-typen

Also Published As

Publication number Publication date
CN108024966A (zh) 2018-05-11
US20200246270A1 (en) 2020-08-06
JP2018530538A (ja) 2018-10-18
JP6841819B2 (ja) 2021-03-10
US10874615B2 (en) 2020-12-29
KR20180052126A (ko) 2018-05-17
WO2017045742A1 (de) 2017-03-23
EP3349733A1 (de) 2018-07-25
CA2998422A1 (en) 2017-03-23
US20190038562A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
DK3174530T3 (en) DIRECT COMPATIBLE POLYVINYL ALCOHOLS
US10828258B2 (en) Directly compressible composition comprising microcrystalline cellulose
Abdelkader et al. Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation
US11883399B2 (en) Bromocriptine formulations
US11040012B2 (en) Pulverulent, directly compressible polyvinyl alcohol grades
US20200246270A1 (en) Formulation having controlled, delayed release of active ingredient
JP2020510626A (ja) 延長した活性物質送達を有する錠剤を製造するための直接打錠可能なマトリックス
JP6855459B2 (ja) 媒体に依存しない活性成分の放出を有する錠剤
WO2017093890A1 (en) Clobazam tablet formulation and process for its preparation
WO2012107090A1 (en) Granulated composition comprising tadalafil and a disintegrant
CN113827576B (zh) 一种活性成分为草酸纳洛解的药物组合物及制备方法
JP7346404B2 (ja) アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法
US20160022661A1 (en) Dosage Form Comprising Crizotinib
AU2024216408B2 (en) Improved bromocriptine formulations
CN119868294B (zh) 一种利格列汀药物组合物及制备方法
WO2021148362A1 (en) Directly compressible polymer combinations for matrix tablets with extended drug release

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application